Literature DB >> 6385643

Overview: pharmacology of ticlopidine.

J L Gordon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6385643     DOI: 10.1007/bf01966992

Source DB:  PubMed          Journal:  Agents Actions Suppl        ISSN: 0379-0363


× No keyword cloud information.
  14 in total

1.  EFFECTS OF BRADYKININ ON FOREARM VENOUS TONE AND VASCULAR RESISTANCE IN MAN.

Authors:  D T MASON; K L MELMON
Journal:  Circ Res       Date:  1965-08       Impact factor: 17.367

2.  Kinin system responses in sepsis after trauma in man.

Authors:  E F Hirsch; T Nakajima; G Oshima; E G Erdös; C M Herman
Journal:  J Surg Res       Date:  1974-09       Impact factor: 2.192

3.  Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation.

Authors:  A D Schreiber; A P Kaplan; K F Austen
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

4.  Plasma kallikrein and Hageman factor in Gram-negative bacteremia.

Authors:  J W Mason; U Kleeberg; P Dolan; R W Colman
Journal:  Ann Intern Med       Date:  1970-10       Impact factor: 25.391

5.  Functional kallikrein inhibition during sepsis and bacterial shock.

Authors:  E S Kalter; B N Bouma
Journal:  Acta Chir Scand Suppl       Date:  1982

6.  Studies of components of the coagulation systems in normal individuals and septic shock patients.

Authors:  N Smith-Erichsen; A O Aasen; M J Gallimore; E Amundsen
Journal:  Circ Shock       Date:  1982

7.  New and rapid functional assay for C1 inhibitor in human plasma.

Authors:  M Schapira; L D Silver; C F Scott; R W Colman
Journal:  Blood       Date:  1982-04       Impact factor: 22.113

Review 8.  Molecular assembly in the contact phase of the Hageman factor system.

Authors:  C G Cochrane; J H Griffin
Journal:  Am J Med       Date:  1979-10       Impact factor: 4.965

9.  Inactivation of kallikrein in human plasma.

Authors:  F van der Graaf; J A Koedam; B N Bouma
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

10.  Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.

Authors:  P C Harpel
Journal:  J Exp Med       Date:  1970-08-01       Impact factor: 14.307

View more
  1 in total

Review 1.  Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.

Authors:  E Saltiel; A Ward
Journal:  Drugs       Date:  1987-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.